Smyd3-mediated immuno-modulation in HPV-negative head and neck squamous cell carcinoma mouse models
Author:
Tsai Daniel E.,
Lovanov Alexei,
Abdelmaksoud Abdalla,
Akhtar Jawad,
Dar Mohd Saleem,
Luff Marie,
McKinnon Katherine,
Kim Sohyoung,
Robbins Yvette,
Huynh Angel,
Murali Madhavi,
Bernard Benjamin,
Sinkoe Andrew,
Luo Xiaolin,
B Karim,
Allen Clint T.,
Saloura VassilikiORCID
Reference35 articles.
1. Cancer statistics, 2018;Siegel;CA A Cancer J. Clin.,2018
2. Human papillomavirus as a marker of the natural history and response to therapy of head and neck squamous cell carcinoma;Ang;Semin. Radiat. Oncol.,2012
3. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study;Burtness;Lancet,2019
4. Cancer Epigenetics, Tumor Immunity, and Immunotherapy;Cao;Trends Cancer,2020
5. Epigenetic silencing of TH1-type chemokines shapes tumour immunity and immunotherapy;Peng;Nature,2015